Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446342 · ClinicalTrials.gov registry record · Phase 1
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
A Phase 1 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00446342 is a Phase 1 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT00446342, a Phase 1 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
Interventions
- DRUG SNS-032 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446342
The ClinicalTrials.gov registry entry for NCT00446342 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNS-032 Injection is the first listed.
NCT00446342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00446342 about?
NCT00446342 is a clinical study titled "Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies". The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
What is the current status of trial NCT00446342?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2007-02. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00446342?
The interventions under investigation include: SNS-032 Injection (DRUG).
Who is sponsoring clinical trial NCT00446342?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.